| Patient | Fannie Lou Hamer |
|---|---|
| Date of birth | 1976-10-06 |
| Identifiers | MRN HR-ML031-SYN; SSN (made up) 000-31-2479 |
| Document date | 2026-11-01 |
| Author | Lorraine Batiste-Hill, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing care at the rural community health center for high blood pressure readings, thirst and frequent urination, leg and back aching, and reduced vision in the left eye since an old injury, with consent-based, trauma-informed care and a social needs screen. Concerns: She wants nothing done to her body without being told first what it is and why, and wants the right to say no; She wants to stay well enough to keep working for her community; She worries about the cost of medicines and getting to appointments. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin extended-release 500 mg oral tablet, one tablet with the evening meal for one week, then two tablets with the evening meal | Two tablets with the evening meal (after one week of one tablet) | Oral route | 2026-03-09 to 2026-07-13 | completed | S |
| Metformin extended-release 500 mg oral tablet, three tablets with the evening meal | Three tablets with the evening meal | Oral route | 2026-07-13 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Amlodipine 5 mg and benazepril 20 mg combined oral capsule, one capsule daily | One capsule daily | Oral route | 2026-03-23 | active | S |
| Dapagliflozin 10 mg oral tablet, one tablet daily; stop on days of vomiting, diarrhea or not eating, and before surgery | One tablet daily, with sick-day rules | Oral route | 2026-03-23 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram, after the purpose was explained and she agreed, with a female assistant | 2026-03-09 to 2026-03-09 | completed | S |
| Comprehensive diabetic foot examination with a 10-g monofilament, vibration and pulses, with her consent | 2026-03-09 to 2026-03-09 | completed | S |
| Ultrasound of both kidneys and the bladder at the health center, after the purpose and steps were explained and she agreed, with a female sonographer and her chosen companion present | 2026-03-23 to 2026-03-23 | completed | S |
| Retinal photographs of both eyes in the clinic without dilating drops, with her consent | 2026-05-04 to 2026-05-04 | completed | S |
| Advance care planning conversation, about 25 minutes | 2026-09-14 to 2026-09-14 | completed | S |
| Screening mammogram, both breasts, after the steps were explained and she agreed, with a female technologist and the community health worker accompanying her | 2026-10-05 to 2026-10-05 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-03-23 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-03-23 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-03-23 | Tetanus, diphtheria, and acellular pertussis vaccine (Tdap) | completed | S |
| 2026-05-04 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-10-19 | Influenza vaccine, inactivated, this season | completed | S |
| 2026-10-19 | COVID-19 vaccine, mRNA, this season | completed | S |
| 2026-10-19 | Recombinant zoster vaccine, dose 1 of 2 | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1961 | Operation to remove a uterine tumor, during which a hysterectomy was performed without her knowledge or informed consent; she calls it a "Mississippi appendectomy". Whether the cervix was removed is not known; no operative record is available | D (CLM-0003) |
| June 9, 1963 | Beaten in the Winona jail, with lasting injuries: permanent kidney damage, a blood clot in the left eye with reduced vision in that eye, and injuries to her legs | D (CLM-0005, CLM-0006) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| She wants nothing done to her body without being told first what it is and why, and wants the right to say no | active | S |
| She wants to stay well enough to keep working for her community | active | S |
| She worries about the cost of medicines and getting to appointments | active | S |
Most recent measures: Hemoglobin A1c/Hemoglobin.total in Blood 6.9 on 2026-10-19; Glucose [Mass/volume] in Serum or Plasma 238 on 2026-03-09; Sodium [Moles/volume] in Serum or Plasma 140 on 2026-05-04; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-10-19; Creatinine [Mass/volume] in Serum or Plasma 1 on 2026-10-19; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 69 on 2026-10-19; Albumin/Creatinine [Mass Ratio] in Urine 41 on 2026-10-19; Cholesterol [Mass/volume] in Serum or Plasma 154 on 2026-05-04; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 80 on 2026-05-04; Cholesterol in HDL [Mass/volume] in Serum or Plasma 46 on 2026-05-04; Triglyceride [Mass/volume] in Serum or Plasma 142 on 2026-05-04; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 26 on 2026-05-04; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 22 on 2026-03-09; Hemoglobin [Mass/volume] in Blood 12.6 on 2026-03-09; Platelets [#/volume] in Blood by Automated count 268 on 2026-03-09; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 2026-03-09; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-07-13; Accountable health communities (AHC) health-related social needs screening (HRSN) tool 1 on 2026-10-19; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 0 on 2026-09-14 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, newly diagnosed: A1c 8.6% and random glucose 238 mg/dL with thirst and frequent urination; synthetic modern episode linked to the diabetes documented in her later life | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes is documented only at the end of her life. |
| Elevated blood pressure at intake (164/98 mmHg), without a diagnosis of hypertension; home readings for one week to confirm | resolved | confirmed | R03.0 | S — Synthetic presenting finding, superseded by the confirmed diagnosis at two weeks. |
| Albumin in the urine (urine albumin-to-creatinine ratio 88 mg/g) and eGFR 73, in a woman whose kidneys were injured in a beating years ago; to be repeated and investigated | resolved | confirmed | R80.9 | S — Synthetic presenting finding, superseded by the kidney diagnosis at two weeks; the old kidney injury is documented. |
| Hypertension, stage 2, confirmed by home readings (average 152/94 mmHg), with chronic kidney disease; synthetic modern episode linked to the hypertension reported in her later life | active | confirmed | I12.9 | S — Synthetic modern diagnosis; hypertension is reported only at the end of her life. |
| Chronic kidney disease G2 A2 (eGFR 73, albumin-to-creatinine ratio 88 to 96 mg/g), with a small, scarred right kidney on ultrasound consistent with old injury; diabetes and high blood pressure likely contribute | active | confirmed | N18.2 | S — Synthetic kidney findings anchored to the documented permanent kidney damage. |
| Type 2 diabetes with diabetic chronic kidney disease (coded with the kidney disease by convention) | active | confirmed | E11.22 | S — Synthetic modern coding. |
| Food insecurity: food runs out before the end of most months | active | confirmed | Z59.41 | S — Synthetic social need found on the screen. |
| Transportation insecurity: no car; the health center is a long drive away and rides are hard to arrange | active | confirmed | Z59.82 | S — Synthetic social need anchored to her rural Delta home. |
| Hyperlipidemia: LDL 146 mg/dL | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-09 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.6 | % | Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for her | High | S |
| 2026-03-09 | Glucose [Mass/volume] in Serum or Plasma | 238 | mg/dL | Random sample; 200 mg/dL or higher with symptoms is diagnostic of diabetes | High | S |
| 2026-03-09 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-03-09 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-03-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 73 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-03-09 | Albumin/Creatinine [Mass Ratio] in Urine | 88 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 2026-03-09 | Cholesterol [Mass/volume] in Serum or Plasma | 228 | mg/dL | <=199 mg/dL | High | S |
| 2026-03-09 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 146 | mg/dL | Goal below 70 mg/dL with diabetes and kidney disease | High | S |
| 2026-03-09 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 44 | mg/dL | >=50 mg/dL | Low | S |
| 2026-03-09 | Triglyceride [Mass/volume] in Serum or Plasma | 190 | mg/dL | <=149 mg/dL | High | S |
| 2026-03-09 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-35 U/L | Normal | S |
| 2026-03-09 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 10-35 U/L | Normal | S |
| 2026-03-09 | Hemoglobin [Mass/volume] in Blood | 12.6 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-03-09 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-03-09 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 2026-03-09 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | 3 | {score} | S | ||
| 2026-03-23 | Albumin/Creatinine [Mass Ratio] in Urine | 96 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 2026-05-04 | Sodium [Moles/volume] in Serum or Plasma | 140 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.7 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 66 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-05-04 | Cholesterol [Mass/volume] in Serum or Plasma | 154 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-05-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 80 | mg/dL | Goal below 70 mg/dL with diabetes and kidney disease | Normal | S |
| 2026-05-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 46 | mg/dL | >=50 mg/dL | Low | S |
| 2026-05-04 | Triglyceride [Mass/volume] in Serum or Plasma | 142 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-05-04 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 26 | U/L | 7-35 U/L | Normal | S |
| 2026-07-13 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.3 | % | Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for her | High | S |
| 2026-07-13 | Albumin/Creatinine [Mass Ratio] in Urine | 52 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 2026-07-13 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-07-13 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-07-13 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 67 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-07-13 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-07-13 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | 1 | {score} | S | ||
| 2026-10-19 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.9 | % | Below 5.7% is normal; 6.5% or higher is diabetes; goal below 7% for her | High | S |
| 2026-10-19 | Albumin/Creatinine [Mass Ratio] in Urine | 41 | mg/g | Below 30 mg/g normal (A1); 30 to 300 moderately increased (A2) | High | S |
| 2026-10-19 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-19 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-10-19 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 69 | mL/min/{1.73_m2} | 90 or higher is normal; 60 to 89 is mildly decreased (G2) | Low | S |
| 2026-10-19 | Accountable health communities (AHC) health-related social needs screening (HRSN) tool | 1 | {score} | S | ||
| 2026-09-14 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-09 | Body height | 163 | cm | S |
| 2026-03-09 | Body weight | 93 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 35 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 164 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 84 | /min | S |
| 2026-03-09 | Respiratory rate | 16 | /min | S |
| 2026-03-09 | Body temperature | 36.8 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-23 | Body height | 163 | cm | S |
| 2026-03-23 | Body weight | 92.6 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 34.9 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 156 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 96 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 82 | /min | S |
| 2026-03-23 | Respiratory rate | 16 | /min | S |
| 2026-03-23 | Body temperature | 36.7 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-05-04 | Body height | 163 | cm | S |
| 2026-05-04 | Body weight | 91.8 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 34.6 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 78 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.6 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-07-13 | Body height | 163 | cm | S |
| 2026-07-13 | Body weight | 90.9 | kg | S |
| 2026-07-13 | Body mass index (BMI) [Ratio] | 34.2 | kg/m2 | S |
| 2026-07-13 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-07-13 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-07-13 | Heart rate | 76 | /min | S |
| 2026-07-13 | Respiratory rate | 16 | /min | S |
| 2026-07-13 | Body temperature | 36.9 | Cel | S |
| 2026-07-13 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-19 | Body height | 163 | cm | S |
| 2026-10-19 | Body weight | 90 | kg | S |
| 2026-10-19 | Body mass index (BMI) [Ratio] | 33.9 | kg/m2 | S |
| 2026-10-19 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-10-19 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-10-19 | Heart rate | 74 | /min | S |
| 2026-10-19 | Respiratory rate | 16 | /min | S |
| 2026-10-19 | Body temperature | 36.7 | Cel | S |
| 2026-10-19 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-09-14 | Body height | 163 | cm | S |
| 2026-09-14 | Body weight | 90.4 | kg | S |
| 2026-09-14 | Body mass index (BMI) [Ratio] | 34 | kg/m2 | S |
| 2026-09-14 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-09-14 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-09-14 | Heart rate | 74 | /min | S |
| 2026-09-14 | Respiratory rate | 16 | /min | S |
| 2026-09-14 | Body temperature | 36.7 | Cel | S |
| 2026-09-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-03-09 | Establishing care at the rural community health center for high blood pressure readings, thirst and frequent urination, leg and back aching, and reduced vision in the left eye since an old injury, with consent-based, trauma-informed care and a social needs screen | finished | S |
| 2026-03-23 | Two-week review of home blood pressure readings and the repeat urine test, with a kidney ultrasound and a nephrology telehealth consultation from the health center | finished | S |
| 2026-05-04 | Six-week review: blood pressure, kidney function and potassium after the new medicines, lipids, retinal photographs, and benefits | finished | S |
| 2026-07-13 | Four-month review: A1c, urine albumin, kidney function, mood, social needs, and the metformin dose | finished | S |
| 2026-10-19 | Seven-month review: A1c, urine albumin, kidney function, seasonal and age-50 vaccines, screening results, and plans for the winter | finished | S |
| 2026-09-14 | Periodic adult preventive visit | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Consent-based, trauma-informed care at every visit: explain each examination, test and procedure beforehand (what it is, why, what it involves, the alternatives, including not doing it), ask her agreement and record it, offer a chaperone or companion of her choosing, let her stop at any time, never perform an unplanned procedure, and keep the plan in writing; written consent for any procedure beyond routine tests | completed | GL-SAMHSA-TIP57-2014, GL-AMA-CONSENT, GL-ACOG-CONSENT-2021 | S |
| Nephrology consultation by telehealth from the health center, with the community health worker present, for albumin in the urine and reduced kidney function in a woman with an old kidney injury, new diabetes and high blood pressure readings | completed | GL-KDIGO-CKD-2024, GL-ADA-CKD-2026 | S |
| Blood pressure: a validated home monitor with a large cuff, provided by the health center, with readings twice a day for seven days to confirm the diagnosis; less salt, using foods she can get; recheck in two weeks | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Diabetes: metformin extended-release once daily, an A1c every three months until at goal, diabetes self-management education in a group class at the health center, and no medicine that can cause low blood sugar | completed | GL-ADA-2026, GL-CMID-2026 | S |
| Kidneys: repeat the urine albumin test, a kidney ultrasound with the consultation, no ibuprofen or naproxen, and kidney function and potassium checks after any blood pressure or kidney medicine is started | completed | GL-KDIGO-CKD-2024, GL-ADA-CKD-2026 | S |
| Cardiovascular risk: atorvastatin 40 mg with a lipid panel at four to twelve weeks, a baseline ECG, and TSH at diagnosis | completed | GL-ADA-2026, GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Eyes and feet: retinal photographs in the clinic, so that no separate trip is needed; a comprehensive foot examination yearly; daily foot checks at home, callus care at the health center and well-fitting shoes | completed | GL-ADA-RETFOOT-2026 | S |
| Social needs, with the community health worker: the AHC health-related social needs screen at intake and every few months; help applying for SNAP and the Low Income Home Energy Assistance Program; the health center's food pantry and produce program; 211 for other local help; rides arranged for every visit and laboratory test; the sliding-fee scale; 90-day medicine supplies at the discount pharmacy, and phone visits when travel is not possible | completed | GL-AHC-HRSN, GL-ADA-POP-2026, GL-SNAP, GL-LIHEAP | S |
| Shared decisions and the team: Dr. Batiste-Hill, a nurse, the community health worker and the pharmacist review the plan with her; medicines chosen for cost, once-daily dosing and her preferences; she decides what she accepts | completed | GL-ADA-2026, GL-ACOG-CONSENT-2021 | S |
| Mood and stress: PHQ-9 at intake and at four months, asked privately; counseling offered at her choice | completed | GL-USPSTF-DEP-2023, GL-CMID-2026 | S |
| Vaccines: pneumococcal, hepatitis B and Tdap offered, explained and given only with her agreement; influenza and COVID-19 each autumn | completed | GL-CDC-IMZ-2026 | S |
| On the consultant's advice: amlodipine 5 mg with benazepril 20 mg in one daily capsule and dapagliflozin 10 mg daily with sick-day rules; potassium and creatinine one to two weeks after starting; urine albumin again at three to four months; blood pressure goal below 130/80; review of kidney treatment by telehealth if albumin stays raised | completed | GL-KDIGO-CKD-2024, GL-ADA-CKD-2026, GL-AHA-HTN-2025 | S |
| Laboratory checks on the days she is already at the health center, with a ride arranged in advance for any extra check; home blood draw by the mobile phlebotomy service when no ride can be found | completed | GL-ADA-POP-2026, GL-AHC-HRSN | S |
| Metformin extended-release increased to 1,500 mg with the evening meal, because the A1c was still above goal | completed | GL-ADA-2026, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Every examination, test and procedure explained first and done only with her documented agreement, with a chaperone of her choosing, at every visit | 2026-10-19 | completed | Consent documented for every examination, blood draw, ultrasound, photograph, vaccine and screening test; she declined a breast and a pelvic examination, and that was respected | S |
| Blood pressure below 130/80 mmHg in the clinic and at home within six months | 2026-10-19 | completed | 124/76 in the clinic; home average 126/78 | S |
| A1c below 7% within six to nine months, without low blood sugar | 2026-10-19 | completed | 6.9% at seven months; no low blood sugar | S |
| Urine albumin-to-creatinine ratio lower by at least 30% within six months | 2026-10-19 | completed | 88 to 96 mg/g at baseline; 41 mg/g at seven months | S |
| Food and utility needs met through benefits, and a dependable way to reach every visit and laboratory test | 2026-10-19 | active | SNAP and energy assistance in place; rides arranged for every visit after one missed laboratory check; transportation still uncertain on some days | S |
| LDL cholesterol below 70 mg/dL | 2026-10-19 | active | 146 to 80 mg/dL on atorvastatin; recheck with the yearly panel | S |